Unknown

Dataset Information

0

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?


ABSTRACT: The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new reflex biomarker for guiding first-line treatment in patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of immune checkpoint inhibitors and chemotherapy as the first-line treatment; however, this strategy has not yet been validated by phase III trial data and its interplay with PD-L1 status still requires clarification.In this manuscript we review the contradictory results of recent phase III trials with immune checkpoint inhibitors in the first-line setting, the potential reasons for discrepancies, and some of the remaining open questions related to the positioning of immune checkpoint inhibitors in the first-line setting of non-small cell lung cancer.

SUBMITTER: Remon J 

PROVIDER: S-EPMC5346853 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Remon Jordi J   Besse Benjamin B   Soria Jean-Charles JC  

BMC medicine 20170313 1


The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new reflex biomarker for guiding first-line treatment in patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of immune checkpoint inhibitors  ...[more]

Similar Datasets

| S-EPMC6318566 | biostudies-literature
| S-EPMC5074862 | biostudies-literature
| S-EPMC5727014 | biostudies-literature
| S-EPMC3425086 | biostudies-literature
| S-EPMC4185902 | biostudies-literature
| S-EPMC7275499 | biostudies-literature
| S-EPMC3426440 | biostudies-literature
| S-EPMC8276096 | biostudies-literature
| S-EPMC6287568 | biostudies-other
| S-EPMC7274841 | biostudies-literature